Human respiratory syncytial virus (hRSV) infection affects mainly the lower respiratory system (e.g., lungs), and can cause severe lung infections, including bronchiolitis (infection of small airways in the lungs) and pneumonia (an infection of the lungs), especially in the high-risk groups such as:
- Premature babies
- Children younger than 2 years old with chronic lung disease or certain heart problems
- Adults 65 years and older
- People with weakened immune systems, such as from HIV infection, organ transplants, or specific medical treatments like chemotherapy
Our goal is to develop a fruit-based edible (oral) vaccine against human respiratory syncytial virus (hRSV), with an oral-drop-vaccine developed for infants.
Dennis E. Buetow, Ph.D.
Chief Executive Officer/Director/Vice-President:
S. Indu Rupassara, Ph.D.